Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Platinum-Resistant Ovarian Carcinoma
0.010 Biomarker disease BEFREE The AGO-OVAR 2.29/ENGOT-ov14/PENELOPE prospectively randomized phase III trial evaluated the addition of pertuzumab to chemotherapy in patients with platinum-resistant ovarian carcinoma with low tumor human epidermal growth factor receptor 3 (HER3) mRNA expression. 27269942 2016